A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea

Journal of Infectious Diseases

Volumn 185, Issue 6, 2002, Pages 820-827

  Genton, Blaise ^a,g   Betuela, Inoni ^a   Felger, Ingrid ^a   Al Yaman, Fadwa ^a   Anders, Robin F ^b,e   Saul, Allan ^d,e   Rare, Lawrence ^a   Baisor, Moses ^a   Lorry, Kerry ^a   Brown, Graham V ^b   Pye, David ^c   Irving, David O ^f   Smith, Thomas A ^g   Beck, Hans Peter ^g   Alpers, Michael P ^a  

^a PAPUA NEW GUINEA INSTITUTE OF MEDICAL RESEARCH   (Papua New Guinea)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c CSL   (Australia)

^d QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^e The Cooperative Research Centre for Vaccine Technology   (Australia)

^f Biotechnology Australia   (Australia)

^g SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; MEROZOITE SURFACE PROTEIN 2;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALARIA; NONHUMAN; PAPUA NEW GUINEA; PHASE 2 CLINICAL TRIAL; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT INDICATION; VACCINATION;

ANIMALS; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; ERYTHROCYTES; HUMANS; MALARIA VACCINES; MALARIA, FALCIPARUM; PAPUA NEW GUINEA; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PREVALENCE; VACCINATION; VACCINES, SYNTHETIC;

EID: 0037086437     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/339342     Document Type: Article

References (31)

1. From genomics to vaccines: Malaria as a model system
2. Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers
3. The Malaria Vaccine Epidemiology and Evaluation Project of Papua New Guinea: Rationale and baseline studies
4. Assessment of the role of the humoral response to Plasmodium falciparum MSP2 compared to RESA and SPf66 in protecting Papua New Guinean children from clinical malaria
5. Assessment of the role of naturally acquired antibody levels to Plasmodium falciparum merozoite surface protein-1 in protecting Papua New Guinean children from malaria morbidity
6. Association between cellular response (IL-4) to RESA/Pf155 and protection from clinical malaria among Papua New Guinean children living in a malaria endemic area
7. Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720
8. Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant
9. Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea
10. Structural diversity in the 45-kilodalton merozoite surface antigen of Plasmodium falciparum
11. The precursor to major merozoite surface antigens: Structure and role in immunity
12. Structural diversity in the Plasmodium falciparum merozoite surface antigen 2
13. Safety, immunogenicity, and pilot efficacy of Plasmodium falciparum sporozoite and asexual blood-stage combination vaccine in Swiss adults
14. Plasmodium falciparum ring-infected erythrocyte surface antigen is released from merozoite dense granules after erythrocyte invasion
15. Spatial and temporal variation in abundance of Anopheles (Diptera:Culicidae) in a malaria endemic area in Papua New Guinea
16. The epidemiology of malaria in the Wosera area, East Sepik Province, Papua New Guinea, in preparation for vaccine trials. I. Malariometric indices and immunity
17. The epidemiology of malaria in the Wosera area, East Sepik Province, Papua New Guinea, in preparation for vaccine trials. II. Mortality and morbidity
18. Duration of protection and age-dependence of the effects of the SPf66 malaria vaccine in African children exposed to intense transmission of Plasmodium falciparum
19. Genotypes of merozoite surface protein 2 of Plasmodium falciparum in Tanzania
20. Malaria: How useful are clinical criteria for improving the diagnosis in a highly endemic area?
21. Relationships between Plasmodium falciparum infection and morbidity in a highly endemic area
22. Effect of vitamin A supplementation on morbidity due to Plasmodium falciparum in young children in Papua New Guinea: A randomised trial
23. Mortality and morbidity from malaria among children in a rural area of The Gambia, West Africa
24. What does a single determination of malaria parasite density mean? A longitudinal survey in Mali
25. Carriage of pneumococci after pneumococcal vaccination
26. Vaccination against colonizing bacteria with multiple serotypes
27. Immunization of monkeys with a 140 kilodalton merozoite surface protein of Plasmodium knowlesi malaria: Appearance of alternate forms of this protein
28. Plasmodium falciparum: Extensive polymorphism in merozoite surface antigen 2 alleles in an area with endemic malaria in Papua New Guinea
29. Genetic analysis of Plasmodium falciparum infections on the northwestern border of Thailand
30. Plasmodium falciparum: Malaria nrorbidity is associated with specific merozoite surface antigen 2 genotypes